NMDP and CIBMTR to Present Research Advancing Transplant Access and Cell Therapy Innovation at ASH 2025 NMDP℠, a leading global nonprofit dedicated to advancing cell therapy, and the CIBMTR® (Center…
PharmaJet to Showcase Advancements in Intradermal Needle-Free Delivery at ASTMH Annual Meeting PharmaJet®, a leading company focused on transforming injectable delivery through needle-free technology, announced that it will present new…
Zetagen Therapeutics Announces Presentation of Promising Phase 2a Data Demonstrating Complete Responses in Metastatic Breast Cancer Bone Lesions at 2025 SABCS Zetagen Therapeutics, a privately held clinical-stage biopharmaceutical company developing…
Serenity Mental Health Centers Expands Access to Breakthrough Ketamine Treatment in Colorado Springs Serenity Mental Health Centers, one of the nation’s fastest-growing providers of advanced psychiatric care, has announced the…
Zoetis Appoints Kevin Esch as New R&D President to Succeed Rob Polzer in 2026, Marking a Strategic Leadership Transition in Global Animal Health Innovation Zoetis Inc. (NYSE: ZTS), the world’s…
Vertex Pharmaceuticals Reports Robust Third Quarter 2025 Results and Refines Full-Year Outlook as Pipeline Momentum Accelerates Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX), a global leader in genetic and transformative medicine, today…
Genetix Biotherapeutics to Highlight U.S. Gene Therapy Implementation and Patient Experience Data at ASH 2025 Genetix Biotherapeutics Inc. announced that an analysis of recent patient experience data from the U.S.…
PureTech’s Gallop Oncology to Present Promising Phase 1b Data of LYT-200 in Relapsed/Refractory AML at the 2025 ASH Annual Meeting PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the…
DoseMe Expands Precision Dosing Leadership with Strategic Acquisition of Firstline to Deliver Comprehensive Clinical Decision Support in the Global Fight Against Infectious Diseases DoseMe, a global leader in model-informed precision…
Auna S.A. Reports Early Results of Cash Tender Offer and Consent Solicitation for 10.000% Senior Secured Notes Due 2029 Auna S.A. (NYSE: AUNA), a Luxembourg-based public limited liability company and…
Vistagen Completes Phase 3 PALISADE-3 Trial Evaluating Fasedienol for Acute Treatment of Social Anxiety Disorder Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company advancing neuroscience through innovative nose-to-brain therapeutics, announced…
Kyowa Kirin International Appoints Julie Dehaene-Puype as President, Ushering in a New Era of Leadership and Growth Kyowa Kirin International (“KKI”), a regional group company of Kyowa Kirin Co., Ltd.…
